MA28002A1 - Traitement de conditions inflammatoires aigues. - Google Patents
Traitement de conditions inflammatoires aigues.Info
- Publication number
- MA28002A1 MA28002A1 MA28824A MA28824A MA28002A1 MA 28002 A1 MA28002 A1 MA 28002A1 MA 28824 A MA28824 A MA 28824A MA 28824 A MA28824 A MA 28824A MA 28002 A1 MA28002 A1 MA 28002A1
- Authority
- MA
- Morocco
- Prior art keywords
- acute inflammatory
- groups
- treatment
- inflammatory conditions
- elements
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 title abstract 3
- 230000004968 inflammatory condition Effects 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 125000003128 glycerophosphate group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G19/00—Compounds of tin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G15/00—Compounds of gallium, indium or thallium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Manufacturing & Machinery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention a trait à un procédé pour la prévention ou le traitement d'un trouble inflammatoire aigu, comprenant l'administration à un patient d'une quantité efficace d'éléments pharmaceutiquement acceptables portant un nombre efficace de groupes contenant du phosphate présentés ou aptes à être présentés à la surface desdits éléments, les groupes contenant du phosphate comportant une pluralité de groupes glycérophosphate ou de groupes transformables en de tels groupes, pour l'inhibition et/ou la réduction de la progression d'un trouble inflammatoire aigu, lesdits éléments ayant une taille comprise entre environ 20 nanomètres (nm) à 500 micromètres ($g(m)m).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48907103P | 2003-07-21 | 2003-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28002A1 true MA28002A1 (fr) | 2006-07-03 |
Family
ID=34079469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28824A MA28002A1 (fr) | 2003-07-21 | 2006-02-20 | Traitement de conditions inflammatoires aigues. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070238708A1 (fr) |
| EP (1) | EP1658086A2 (fr) |
| JP (1) | JP2006528136A (fr) |
| KR (1) | KR20060037369A (fr) |
| CN (1) | CN1826123A (fr) |
| AU (1) | AU2004257375A1 (fr) |
| BR (1) | BRPI0412882A (fr) |
| CA (1) | CA2533084A1 (fr) |
| EA (1) | EA200600297A1 (fr) |
| IL (1) | IL173068A0 (fr) |
| MA (1) | MA28002A1 (fr) |
| MX (1) | MXPA06000805A (fr) |
| NO (1) | NO20060820L (fr) |
| WO (1) | WO2005007169A2 (fr) |
| ZA (1) | ZA200601458B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007131329A1 (fr) * | 2006-05-12 | 2007-11-22 | Vasogen Ireland Limited | Traitement des troubles liés au dysfonctionnement du système ubiquitine-protéasome |
| EP2142196A4 (fr) | 2007-03-29 | 2010-06-30 | Nat Jewish Health | Lipides tensioactifs, compositions et utilisation de ceux-ci |
| CN105434354A (zh) * | 2009-06-03 | 2016-03-30 | 斯昆申技术控股有限责任公司 | 用于治疗深部组织疼痛的制剂 |
| US20120232034A1 (en) * | 2009-08-21 | 2012-09-13 | Henk-Andre Kroon | Vesicular formulations |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| ES2879383T3 (es) | 2015-06-30 | 2021-11-22 | Sequessome Tech Holdings Limited | Fórmulas mixtas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346526C2 (de) * | 1983-12-22 | 1986-12-11 | A. Nattermann & Cie GmbH, 5000 Köln | Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen |
| FR2658418B1 (fr) * | 1990-02-20 | 1994-09-02 | Synthelabo | Compositions pharmaceutiques a base de phospholipides. |
| WO1995023592A1 (fr) * | 1994-03-04 | 1995-09-08 | The University Of British Columbia | Compositions a base de liposomes et procedes de traitement de l'atherosclerose |
| US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
| EP1133301A1 (fr) * | 1998-11-26 | 2001-09-19 | Britannia Pharmaceuticals Limited | Combinaisons antiasthmatiques a base de phospholipides tensio-actifs |
| EP1248628A4 (fr) * | 1999-12-14 | 2004-08-04 | Sky High Llc | Compositions phospholipidiques utiles en tant qu'agents anti-inflammatoires |
| US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| CA2368656A1 (fr) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Appariement recepteur-ligand pour produire une reeaction anti-inflammatoire |
| US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| WO2004024123A1 (fr) * | 2002-09-16 | 2004-03-25 | Vasogen Ireland Limited | Acceleration du retablissement suite a des traumas |
| WO2004037270A1 (fr) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Regulation de cyclooxygenase avec des liposomes pg |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
-
2004
- 2004-07-20 EP EP04761575A patent/EP1658086A2/fr not_active Withdrawn
- 2004-07-20 BR BRPI0412882-6A patent/BRPI0412882A/pt not_active IP Right Cessation
- 2004-07-20 US US10/565,360 patent/US20070238708A1/en not_active Abandoned
- 2004-07-20 JP JP2006520639A patent/JP2006528136A/ja not_active Withdrawn
- 2004-07-20 EA EA200600297A patent/EA200600297A1/ru unknown
- 2004-07-20 ZA ZA200601458A patent/ZA200601458B/en unknown
- 2004-07-20 CN CNA2004800212870A patent/CN1826123A/zh active Pending
- 2004-07-20 WO PCT/CA2004/001053 patent/WO2005007169A2/fr not_active Ceased
- 2004-07-20 MX MXPA06000805A patent/MXPA06000805A/es unknown
- 2004-07-20 CA CA002533084A patent/CA2533084A1/fr not_active Abandoned
- 2004-07-20 AU AU2004257375A patent/AU2004257375A1/en not_active Abandoned
- 2004-07-20 KR KR1020067001122A patent/KR20060037369A/ko not_active Withdrawn
-
2006
- 2006-01-10 IL IL173068A patent/IL173068A0/en unknown
- 2006-02-20 NO NO20060820A patent/NO20060820L/no not_active Application Discontinuation
- 2006-02-20 MA MA28824A patent/MA28002A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060037369A (ko) | 2006-05-03 |
| MXPA06000805A (es) | 2006-04-18 |
| EP1658086A2 (fr) | 2006-05-24 |
| AU2004257375A1 (en) | 2005-01-27 |
| US20070238708A1 (en) | 2007-10-11 |
| IL173068A0 (en) | 2006-06-11 |
| BRPI0412882A (pt) | 2006-10-03 |
| CA2533084A1 (fr) | 2005-01-27 |
| EA200600297A1 (ru) | 2006-08-25 |
| ZA200601458B (en) | 2007-05-30 |
| WO2005007169A3 (fr) | 2005-09-22 |
| JP2006528136A (ja) | 2006-12-14 |
| CN1826123A (zh) | 2006-08-30 |
| WO2005007169A2 (fr) | 2005-01-27 |
| NO20060820L (no) | 2006-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57908B1 (fr) | Composés macrocycliques substitués et méthodes de traitement associées | |
| Frieling et al. | Treatment of severe lichen planus with mycophenolate mofetil | |
| EP3496733B1 (fr) | Composition destinée à être utilisée dans le traitement d'un trouble dépressif majeur | |
| MA52219B1 (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| FR2918571B1 (fr) | Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales | |
| MA62910A1 (fr) | Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques | |
| Kleinfelder et al. | Fluoroquinolones in the treatment of Actinobacillus actinomycetemcomitans‐associated periodontitis | |
| Çınar et al. | Effectiveness and safety of clonazepam, pregabalin, and alpha lipoic acid for the treatment of burning mouth syndrome | |
| BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
| WO2006055621A2 (fr) | Inhibiteurs de l'histone desacetylase et leurs methodes d'utilisation | |
| Lindhe et al. | The effect of metronidazole therapy on human periodontal disease. | |
| EA200600297A1 (ru) | Лечение острого воспалительного состояния | |
| Güngör et al. | Penile pyoderma gangrenosum | |
| CN1430514A (zh) | 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 | |
| Zlotnik et al. | Experimental production of actinomycetoma in BALB/c mice | |
| Phillips et al. | Melioidosis in a patient with chronic rhinosinusitis | |
| Sheranov | Modern aspects of the etiology, pathogenesis, and individualized therapy of peptic ulcer disease | |
| AU729675B2 (en) | Treatment of urinary incontinence and compositions for use therein | |
| AU2001273228A1 (en) | Methods of treatment comprising administration of substance P | |
| KR20040018377A (ko) | 유기체에서의 기생성 진균의 확인 및 그의 치료법 | |
| WO2020168337A4 (fr) | Compositions et méthodes pour le traitement de la dépression et d'autres troubles | |
| Yuzhakov et al. | PD12-11 24-HOUR URINE CALCIUM OXALATE SUPERSATURATION RISK CORRELATES WITH CT VOLUMETRIC CALCIUM OXALATE STONE GROWTH | |
| Park et al. | Review on the Different Approach between Alzheimer’s and Parkinson’s Disease | |
| WO2003103610A3 (fr) | Analogues de mappicines, procedes d'inhibition de transcriptase inverse retrovirale et methodes de traitement de retrovirus |